{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:36:35Z","timestamp":1767825395253,"version":"3.49.0"},"reference-count":36,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.3892\/ol.2015.3876","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T13:35:39Z","timestamp":1446730539000},"page":"355-359","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB"],"prefix":"10.3892","volume":"11","author":[{"given":"FENG","family":"XIAO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YING","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WEILAI","family":"XU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LIANGSHUN","family":"YOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHUNMEI","family":"YANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HUI","family":"LIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WENBIN","family":"QIAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,11,5]]},"reference":[{"key":"key20180108095436_b1-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1182\/blood-2007-08-078139","article-title":"Myelodysplastic syndromes","volume":"111","author":"Nimer","year":"2008","journal-title":"Blood"},{"key":"key20180108095436_b2-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2005.04.006","article-title":"Management of patients with higher risk myelodysplastic syndromes","volume":"56","author":"Fukumoto","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180108095436_b3-ol-0-0-3876","first-page":"1805","article-title":"Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG)","volume":"9","author":"de Witte","year":"1995","journal-title":"Leukemia"},{"key":"key20180108095436_b4-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2010.31.0854","article-title":"Hypomethylating agents and other novel strategies in myelodysplastic syndromes","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180108095436_b5-ol-0-0-3876","first-page":"21","article-title":"High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF)","volume":"1","author":"Estey","year":"1995","journal-title":"Cytokines Mol Ther"},{"key":"key20180108095436_b6-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V90.8.2969","article-title":"Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy","volume":"90","author":"Estey","year":"1997","journal-title":"Blood"},{"key":"key20180108095436_b7-ol-0-0-3876","first-page":"40","article-title":"Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia","volume":"10","author":"Feldman","year":"1996","journal-title":"Leukemia"},{"key":"key20180108095436_b8-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00280-008-0805-8","article-title":"A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804","volume":"63","author":"Stone","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180108095436_b9-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cncr.22398","article-title":"Phase I\/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy","volume":"109","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Cancer"},{"key":"key20180108095436_b10-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-8722-2-32","article-title":"A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China","volume":"2","author":"Wang","year":"2009","journal-title":"J Hematol Oncol"},{"key":"key20180108095436_b11-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/sj.leu.2404287","article-title":"Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia","volume":"20","author":"Jin","year":"2006","journal-title":"Leukemia"},{"key":"key20180108095436_b12-ol-0-0-3876","first-page":"108","article-title":"Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes","volume":"123","author":"Xu","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"key20180108095436_b13-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1124\/mol.110.068528","article-title":"Bcl-xL is a dominant antiapoptotic protein that inhibits homoharringtonine-induced apoptosis in leukemia cells","volume":"79","author":"Yin","year":"2011","journal-title":"Mol Pharmacol"},{"key":"key20180108095436_b14-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0014-5793(89)81546-7","article-title":"Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation","volume":"257","author":"Tujebajeva","year":"1989","journal-title":"FEBS Lett"},{"key":"key20180108095436_b15-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2010-01-262808","article-title":"Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia","volume":"117","author":"Chen","year":"2011","journal-title":"Blood"},{"key":"key20180108095436_b16-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/10428190701216360","article-title":"Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway","volume":"48","author":"Jie","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"key20180108095436_b17-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1038\/cddis.2012.149","article-title":"Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor","volume":"3","author":"Lindqvist","year":"2012","journal-title":"Cell Death Dis"},{"key":"key20180108095436_b18-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/aps.2009.147","article-title":"Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines","volume":"30","author":"Meng","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"key20180108095436_b19-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1080\/10428190802320368","article-title":"Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells","volume":"49","author":"Meng","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"key20180108095436_b20-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12185-008-0081-8","article-title":"Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin","volume":"87","author":"Kuroda","year":"2008","journal-title":"Int J Hematol"},{"key":"key20180108095436_b21-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"key20180108095436_b22-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"key20180108095436_b23-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1054\/bjoc.2001.2030","article-title":"A prognostic model for ovarian cancer","volume":"85","author":"Clark","year":"2001","journal-title":"Br J Cancer"},{"key":"key20180108095436_b24-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"key20180108095436_b25-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.blre.2013.07.003","article-title":"Current therapy of myelodysplastic syndromes","volume":"27","author":"Zeidan","year":"2013","journal-title":"Blood Rev"},{"key":"key20180108095436_b26-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1046\/j.1365-2141.1997.2973114.x","article-title":"Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders","volume":"98","author":"Wattel","year":"1997","journal-title":"Br J Haematol"},{"key":"key20180108095436_b27-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/sj.leu.2402591","article-title":"EORTC, EBMT, SAKK, GIMEMA Leukemia Groups and the MD Anderson Cancer Center: Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors","volume":"16","author":"Oosterveld","year":"2002","journal-title":"Leukemia"},{"key":"key20180108095436_b28-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplasticsyndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"key20180108095436_b29-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/1097-0142(20011015)92:8<1999::AID-CNCR1538>3.0.CO;2-B","article-title":"High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens","volume":"92","author":"Beran","year":"2001","journal-title":"Cancer"},{"key":"key20180108095436_b30-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2141.1991.tb08616.x","article-title":"Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy","volume":"77","author":"Fenaux","year":"1991","journal-title":"Br J Haematol"},{"key":"key20180108095436_b31-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/ecc.12065","article-title":"A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome","volume":"22","author":"Daver","year":"2013","journal-title":"Eur J Cancer Care (Engl)"},{"key":"key20180108095436_b32-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00432-011-1020-2","article-title":"Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS","volume":"137","author":"Wu","year":"2011","journal-title":"Cancer Res Clin Oncol"},{"key":"key20180108095436_b33-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1080\/10428190903096719","article-title":"Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome","volume":"50","author":"Wu","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"key20180108095436_b34-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","article-title":"Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial","volume":"14","author":"Jin","year":"2008","journal-title":"Lancet Oncol"},{"key":"key20180108095436_b35-ol-0-0-3876","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.leukres.2013.06.023","article-title":"\u03b2-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia","volume":"37","author":"Wang","year":"2013","journal-title":"Leuk Res"},{"key":"key20180108095436_b36-ol-0-0-3876","first-page":"1085","article-title":"Phase I clinical investigation of homoharringtonine","volume":"68","author":"Legha","year":"1984","journal-title":"Cancer Treat Rep"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2015.3876\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:32:35Z","timestamp":1599784355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2015.3876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,5]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,11,5]]},"published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.3892\/ol.2015.3876"],"URL":"https:\/\/doi.org\/10.3892\/ol.2015.3876","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,5]]}}}